| Literature DB >> 34159081 |
Houyi Wei1, Jiandong Gao2, Mingshuai Wang1, Wahafu Wasilijiang3, Pan Ai2, Xiaoguang Zhou1, Liyan Cui1, Liming Song1, Anshi Wu2, Nianzeng Xing3, Yinong Niu1.
Abstract
BACKGROUND: We aimed to examine whether body mass index (BMI) had an impact on clinical outcomes of laparoscopic radical cystectomy with intracorporeal urinary diversion. Furthermore, we analyzed the optimization of enhanced recovery protocols (ERPs) on the impact of BMI on clinical outcomes.Entities:
Keywords: Enhanced recovery protocols (ERPs); body mass index (BMI); intracorporeal urinary diversion (ICUD); post-operative nausea and vomiting (PONV); serum albumin
Year: 2021 PMID: 34159081 PMCID: PMC8185665 DOI: 10.21037/tau-21-171
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Elements of ERPs and CRPs
| Time point | ERPs | CRPs |
|---|---|---|
| Preoperative | 1. Counselling and education of ERPs protocol | 1. None |
| 2. Evaluation of comorbidities and medical optimization | 2. Evaluation of comorbidities and medical optimization | |
| 3. Evaluation of nutritional status, and oral support if needed | 3. None | |
| 4. Thromboprophylaxis: low molecular weight heparin and compression stockings | 4. Compression stockings | |
| Prior to surgery | ||
| 3 d | Normal diet | Low residue diet |
| Oral antibiotics (fluoroquinolones and metronidazole) | ||
| 2 d | Normal diet | Liquid diet |
| Oral antibiotics | ||
| 1 d | Low residue diet | Potable water |
| Laxatives | Enema | |
| Oral antibiotics | ||
| Parenteral nutrition | ||
| 6 h | Potable water | NPO |
| 2 h | NPO | NPO |
| Oral carbohydrate loading 2 h prior to surgery (5 mL/kg) | ||
| 30 min | Intravenous antibiotics; Another dose of intravenous antibiotics if operative time exceeds 3 h | Intravenous antibiotics |
| NGT | NGT intubation after anesthesia and removed after awaking or no NGT use | NGT intubation before surgery and removed after passing flatus |
| Intraoperative | 1. LRC with ICUD | 1. LRC with ICUD |
| 2. General intravenous and epidural anesthesia; removal of epidural catheter after surgery | 2. General intravenous anesthesia | |
| 3. Avoidance of long-acting sedatives and opioids | 3. Conventional anesthetics | |
| 4. Prevention of hypothermia (warm air blower or blanket) | 4. None | |
| 5. Goal-directed fluid administration | 5. None | |
| 6. Local infiltration of ropivacaine before wound closure | 6. None | |
| 7. Intravenous antemetics before awaking | 7. Intravenous antemetics before awaking | |
| 8. Pelvic drainage tube placement | 8. Pelvic drainage tube placement | |
| 9. Patient controlled intravenous analgesia placement | 9. Patient controlled intravenous analgesia placement | |
| Postoperative | 1. Recumbent position | 1. Recumbent position without pillow |
| 2. Opioid-sparing analgesia; NSAIDs for those with VAS more than 4 | 2. Conventional analgesics | |
| 3. Moderate mobilization 4 h after surgery | 3. Prohibition of mobilization on postoperative day 1 | |
| 4. Potable water 6 h after surgery, 50 mL/h; Adding to 100 mL/h on postoperative day 1 if tolerated; resuming liquid diet after passing flatus and converting to normal diet gradually | 4. NPO until passing flatus | |
| 5. Chewing gum 3 times a day until passing flatus, 30 min each time | 5. None | |
| 6. Avoidance of fluid over-infusion, ≤30 mL/kg | 6. None | |
| 7. Thromboprophylaxis: low molecular weight heparin and compression stockings | 7. Thromboprophylaxis: low molecular weight heparin and compression stockings |
ERPs, enhanced recovery protocols; CRPs, conventional recovery protocols; LRC, laparoscopic radical cystectomy; ICUD, intracorporeal urinary diversion; NPO, nil per os; NGT, nasogastric tube; NSAIDs, non-steroidal anti-inflammatory drugs; VAS, visual analogue scale.
Baseline characteristics of patients with group A (<24 kg/m2) and B (≥24 kg/m2)
| Characteristics | Group A (N=37) | Group B (N=46) | P |
|---|---|---|---|
| Mean age (years) | 62.51±10.57 | 61.15±9.21 | 0.533 |
| No. gender, n (%) | 1.000 | ||
| Male | 31 (83.8) | 39 (84.8) | |
| Female | 6 (16.2) | 7 (15.2) | |
| No. American Society of Anesthesiologists, n (%) | 0.246 | ||
| I–II | 34 (91.9) | 37 (80.4) | |
| III | 3 (8.1) | 9 (19.6) | |
| Median age-adjusted Charlson comorbidity index | 3 [2–5] | 4 [2–5] | 0.611 |
| No. transurethral resection of bladder tumor, n (%) | 19 (51.4) | 21 (45.7) | 0.662 |
| No. history of neoadjuvant chemotherapy, n (%) | 10 (27.0) | 4 (8.7) | 0.055 |
| No. history of abdominal surgery, n (%) | 6 (16.2) | 11 (23.9) | 0.426 |
| No. history of smoking, n (%) | 18 (48.6) | 19 (41.3) | 0.515 |
| No. type of urinary diversion, n (%) | 1.000 | ||
| Ileal conduit | 23 (62.2) | 28 (60.9) | |
| Orthotopic ileal neobladder | 14 (37.8) | 18 (39.1) | |
| No. with enhanced recovery protocols, n (%) | 11 (29.7) | 18 (39.1) | 0.488 |
Perioperative results of patients with group A (<24 kg/m2) and B (≥24 kg/m2)
| Variables | Group A (N=37) | Group B (N=46) | P |
|---|---|---|---|
| Median operative time (min) | 360 [300–420] | 360 [308–450] | 0.786 |
| Median estimated blood loss (mL) | 200 [100–300] | 200 [100–275] | 0.756 |
| No. intraoperative blood transfusion, n (%) | 2 (5.4) | 4 (8.7) | 0.882 |
| Median time to liquid diet (day) | 73 [14–108] | 72 [12–96] | 0.102 |
| Median time to pelvic drainage tube removal (day) | 8 [6–11] | 7 [6–11] | 0.878 |
| Median length of stay (day) | 11 [8–15] | 11 [9–15] | 0.927 |
| No. readmission, n (%) | 1 (2.7) | 4 (8.7) | 0.499 |
| No. 30-d overall complication, n (%) | 28 (75.7) | 33 (71.7) | 0.804 |
| No. 30-d minor complication, n (%) | 27 (73.0) | 32 (69.6) | 0.810 |
| Fever | 13 (35.1) | 17 (37.0) | 1.000 |
| PONV | 12 (32.4) | 4 (8.7) | 0.014 |
| Constipation | 14 (37.8) | 13 (28.3) | 0.480 |
| No. 30-d major complication, n (%) | 1 (2.7) | 2 (4.3) | 1.000 |
| Preoperative ALB (g/L) | 39.49±4.85 | 42.29±3.95 | 0.005 |
| Postoperative ALB (g/L) | |||
| POD1 | 27.22±3.61 | 31.41±3.13 | <0.001 |
| POD2 | 27.17±3.61 | 31.24±3.01 | <0.001 |
| POD3 | 27.51±3.73 | 31.49±3.06 | <0.001 |
| ALBmin | 26.23±3.92 | 30.30±3.08 | <0.001 |
| Reduction degree (g/L) | |||
| ÄPOD1 | 12.61±4.50 | 10.87±4.00 | 0.069 |
| ÄPOD2 | 12.25±4.39 | 11.02±3.95 | 0.201 |
| ÄPOD3 | 11.63±4.63 | 11.24±3.74 | 0.711 |
| ÄALBmin | 13.26±4.68 | 11.99±4.19 | 0.197 |
| Reduction proportion, n (%) | |||
| ÄPOD1 | 31.22±9.07 | 25.33±8.25 | 0.003 |
| ÄPOD2 | 30.54±9.32 | 25.72±8.25 | 0.019 |
| ÄPOD3 | 29.08±10.60 | 26.01±7.70 | 0.188 |
| ÄALBmin | 33.08±9.88 | 27.92±8.52 | 0.013 |
Reduction degree = preoperative albumin level − postoperative albumin level; reduction proportion = reduction degree/preoperative albumin level ×100%. PONV, postoperative nausea and vomiting; ALB, albumin; POD, postoperative day; ALBmin, minimum albumin within 3 postoperative days.
30-day complication and perioperative albumin level in ERPs and CRPs group with group A1 (<24 kg/m2) vs. B1 (≥24 kg/m2), and group A2 (<24 kg/m2) vs. B2 (≥24 kg/m2)
| Variables | ERPs | CRPs | |||||
|---|---|---|---|---|---|---|---|
| Group A1 (N=11) | Group B1 (N=18) | P | Group A2 (N=26) | Group B2 (N=28) | P | ||
| No. 30-d complication, n (%) | 7 (63.6) | 9 (50.0) | 0.702 | 21 (80.8) | 24 (85.7) | 0.903 | |
| No. 30-d minor complication, n (%) | 7 (63.6) | 9 (50.0) | 0.702 | 20 (76.9) | 23 (82.1) | 0.741 | |
| Fever | 1 (9.1) | 4 (22.2) | 0.622 | 12 (46.2) | 13 (46.4) | 1.000 | |
| PONV | 1 (9.1) | 2 (11.1) | 1.000 | 11 (42.3) | 2 (7.1) | 0.007 | |
| Constipation | 4 (36.4) | 5 (27.8) | 0.694 | 10 (38.5) | 8 (28.6) | 0.566 | |
| No. 30-d major complication, n (%) | 0 | 0 | – | 1 (3.8) | 2 (7.1) | 1.000 | |
| Mean preoperative ALB (g/L) | 40.69±5.41 | 42.96±4.09 | 0.210 | 38.98±4.62 | 41.85±3.88 | 0.016 | |
| Mean postoperative ALB (g/L) | |||||||
| POD1 | 29.97±2.71 | 32.92±2.47 | 0.006 | 26.00±3.30 | 30.44±3.15 | <0.001 | |
| POD2 | 30.57±2.88 | 32.78±2.36 | 0.042 | 25.62±2.76 | 30.38±3.03 | <0.001 | |
| POD3 | 30.74±2.96 | 32.84±2.38 | 0.060 | 25.73±2.83 | 30.49±3.18 | <0.001 | |
| ALBmin | 29.68±2.63 | 31.81±2.74 | 0.049 | 24.77±3.45 | 29.33±2.93 | <0.001 | |
| Mean reduction degree (g/L) | |||||||
| ÄPOD1 | 10.72±4.32 | 10.04±4.41 | 0.688 | 13.44±4.41 | 11.42±3.69 | 0.074 | |
| ÄPOD2 | 10.12±4.12 | 9.66±4.72 | 0.799 | 13.23±4.23 | 11.78±3.30 | 0.177 | |
| ÄPOD3 | 9.95±4.62 | 9.73±4.10 | 0.898 | 12.55±4.47 | 12.35±3.11 | 0.874 | |
| ÄALBmin | 11.01±4.38 | 11.16±4.80 | 0.935 | 14.20±4.55 | 12.53±3.74 | 0.142 | |
| Mean reduction proportion, n (%) | |||||||
| ÄPOD1 | 25.65±7.52 | 22.80±8.54 | 0.369 | 33.67±8.71 | 26.97±7.77 | 0.005 | |
| ÄPOD2 | 24.20±7.67 | 22.11±9.48 | 0.552 | 33.43±8.66 | 27.73±6.87 | 0.012 | |
| ÄPOD3 | 23.67±9.38 | 22.34±7.99 | 0.706 | 32.06±10.24 | 28.72±6.42 | 0.233 | |
| ÄALBmin | 26.35±7.64 | 25.35±9.38 | 0.769 | 35.93±9.42 | 29.57±7.65 | 0.009 | |
Reduction degree = preoperative albumin level − postoperative albumin level; reduction proportion = reduction degree/preoperative albumin level ×100%. ERPs, enhanced recovery protocols; CRPs, conventional recovery protocols; PONV, postoperative nausea and vomiting; ALB, albumin; POD, postoperative day; ALBmin, minimum albumin within 3 postoperative days.
Univariable and multivariable regression analysis of factors associated with ΔALBmin ≥34%
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | P | Odds ratio (95% CI) | P | ||
| Age (continuous) | 1.003 (0.957–1.050) | 0.906 | – | – | |
| BMI <24 kg/m2 (yes | 3.800 (1.467–9.846) | 0.006 | 2.816 (1.001–7.926) | 0.050 | |
| Sex (male | 1.250 (0.349–4.474) | 0.732 | – | – | |
| aCCI (continuous) | 0.829 (0.662–1.038) | 0.102 | – | – | |
| Operative time (continuous) | 1.003 (0.999–1.007) | 0.109 | – | – | |
| Estimated blood loss (continuous) | 0.999 (0.996–1.002) | 0.561 | – | – | |
| Lymph node yield (continuous) | 1.006 (0.954–1.060) | 0.837 | – | – | |
| Ileal conduit | 0.536 (0.213–1.347) | 0.185 | – | – | |
| CRPs | 3.840 (1.274–11.570) | 0.017 | 3.243 (1.014–10.367) | 0.047 | |
| PONV (yes | 5.989 (1.827–19.630) | 0.003 | 3.901 (1.067–14.256) | 0.040 | |
CI, confidence intervals; BMI, body mass index; aCCI, age-adjusted Charlson Comorbidity Index; ERPs, enhanced recovery protocols; CRPs, conventional recovery protocols; PONV, postoperative nausea and vomiting.